Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13801217 | 1.00 | NR1H2 (0.58) | NR1H2USP2SMN1; SMN2HPGDRECQL | |
| SCHEMBL12035619 | 1.00 | NR1H2 (0.58) | NR1H2USP2SMN1; SMN2HPGDRECQL | |
| SCHEMBL15764146 | 1.00 | NR1H2 (0.58) | NR1H2USP2SMN1; SMN2HPGDRECQL | |
| SCHEMBL20905506 | 0.90 | NR1H2 (0.53) | NR1H2USP2SMN1; SMN2HPGDRECQL | |
| SCHEMBL3118155 | 0.89 | NR1H2 (0.56) | NR1H2USP2SMN1; SMN2HPGDRECQL | |
| SCHEMBL951953 | 0.88 | NR1H2 (0.51) | NR1H2USP2SMN1; SMN2HPGDRECQL | |
| SCHEMBL2202617 | 0.88 | NR1H2 (0.51) | NR1H2USP2SMN1; SMN2HPGDRECQL | |
| SCHEMBL15155084 | 0.88 | NR1H2 (0.51) | NR1H2USP2SMN1; SMN2HPGDRECQL | |
| SCHEMBL2202621 | 0.88 | NR1H2 (0.51) | NR1H2USP2SMN1; SMN2HPGDRECQL | |
| SCHEMBL951952 | 0.88 | NR1H2 (0.51) | NR1H2USP2SMN1; SMN2HPGDRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4271676-A1 | CARBONYL SUBSTITUTED DIAZASPIRO COMPOUNDS AND ITS USE | Bionova Pharmaceuticals (Shanghai) Limited (CN) | 2023-11-08 | — | — | EP | disclosed |
| CN-116829559-A | Carbonyl substituted diazaspiro compounds and uses thereof | 烨辉医药科技(上海)有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-20230140395-A1 | NOVEL IMIDAZOLE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND USE THEREOF | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2023-05-04 | — | — | US | disclosed |
| US-9238039-B2 | Pyrazolo[1,5-A]pyrimidines for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| US-20140154240-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2014-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140154240-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | NR1H2 3787/4885USP2 4730/4885SMN1; SMN2 904/4885 |
| US-20230140395-A1 | NOVEL IMIDAZOLE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND USE THEREOF | MAPKAPK3, MAPK3, MAP3K3 | NR1H2 2841/4885USP2 2732/4885SMN1; SMN2 1853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.